Profile data is unavailable for this security.
About the company
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
- Revenue in USD (TTM)996.61m
- Net income in USD-398.71m
- Incorporated1987
- Employees1.54k
- LocationNovavax Inc700 Quince Orchard RoadGAITHERSBURG 20878United StatesUSA
- Phone+1 (240) 268-2000
- Fax+1 (302) 636-5454
- Websitehttps://www.novavax.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Syndax Pharmaceuticals Inc | 0.00 | -240.63m | 2.08bn | 112.00 | -- | 4.23 | -- | -- | -3.22 | -3.22 | 0.00 | 5.79 | 0.00 | -- | -- | 0.00 | -47.99 | -27.90 | -51.84 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
CG Oncology Inc | 539.00k | -72.33m | 2.20bn | 61.00 | -- | 3.87 | -- | 4,088.66 | -1.13 | -1.13 | 0.0084 | 8.54 | -- | -- | -- | 8,836.07 | -- | -- | -- | -- | -- | -- | -10,551.39 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
Structure Therapeutics Inc (ADR) | 0.00 | -97.68m | 2.20bn | 111.00 | -- | 4.19 | -- | -- | -2.32 | -2.32 | 0.00 | 9.22 | 0.00 | -- | -- | 0.00 | -27.73 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
Recursion Pharmaceuticals Inc | 46.24m | -354.11m | 2.28bn | 500.00 | -- | 4.94 | -- | 49.28 | -1.62 | -1.62 | 0.2112 | 1.69 | 0.078 | -- | 19.86 | 92,470.00 | -59.76 | -- | -69.49 | -- | 10.66 | -- | -765.90 | -- | -- | -- | 0.0028 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
Janux Therapeutics Inc | 7.29m | -55.59m | 2.28bn | 64.00 | -- | 3.48 | -- | 313.01 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
Rocket Pharmaceuticals Inc | 0.00 | -249.31m | 2.30bn | 268.00 | -- | 5.20 | -- | -- | -2.87 | -2.87 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -49.16 | -35.26 | -52.49 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0458 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
Maravai Lifesciences Holdings Inc | 274.10m | -131.04m | 2.31bn | 570.00 | -- | 5.62 | -- | 8.42 | -0.9917 | -0.9917 | 2.08 | 1.63 | 0.1458 | 2.93 | 5.90 | 421,690.80 | -8.49 | 12.67 | -11.29 | 15.46 | 44.03 | 74.79 | -58.27 | 37.32 | 10.47 | -2.02 | 0.4169 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
Protagonist Therapeutics Inc | 314.95m | 162.11m | 2.36bn | 124.00 | 16.38 | 4.21 | 14.49 | 7.50 | 2.46 | 2.46 | 5.25 | 9.56 | 0.7248 | -- | 2.10 | 2,812,080.00 | 37.30 | -35.90 | 40.23 | -41.36 | -- | -- | 51.47 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
Novavax Inc | 996.61m | -398.71m | 2.40bn | 1.54k | -- | -- | -- | 2.41 | -3.18 | -3.18 | 8.46 | -6.18 | 0.6882 | 14.75 | 14.85 | 645,890.50 | -27.53 | -46.06 | -460.95 | -269.57 | 63.04 | -- | -40.01 | -75.94 | 0.8843 | -27.04 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
Fortrea Holdings Inc | 3.01bn | -100.60m | 2.41bn | 16.00k | -- | 1.51 | -- | 0.8004 | -1.13 | -1.37 | 33.82 | 17.81 | 0.7036 | -- | 3.10 | 167,050.00 | -2.35 | -- | -2.84 | -- | 16.64 | -- | -3.35 | -- | -- | 0.2534 | 0.5035 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
Intellia Therapeutics Inc | 52.60m | -485.50m | 2.56bn | 526.00 | -- | 2.46 | -- | 48.60 | -5.37 | -5.37 | 0.5827 | 10.76 | 0.0393 | -- | 2.55 | 100,007.60 | -36.27 | -31.34 | -39.21 | -34.53 | -- | -- | -922.94 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
Iovance Biotherapeutics Inc | 1.90m | -449.64m | 2.59bn | 557.00 | -- | 3.81 | -- | 1,359.48 | -1.82 | -1.82 | 0.0077 | 2.43 | 0.0023 | -- | -- | 3,418.31 | -53.07 | -51.47 | -59.00 | -57.56 | -846.22 | -- | -23,615.70 | -137,873.80 | 4.42 | -- | 0.0015 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
PTC Therapeutics, Inc. | 927.56m | -579.22m | 2.61bn | 988.00 | -- | -- | -- | 2.82 | -7.69 | -7.69 | 12.28 | -11.66 | 0.5459 | 2.33 | 4.64 | 938,823.90 | -34.09 | -26.71 | -48.63 | -33.46 | 92.88 | 93.94 | -62.45 | -83.80 | 1.98 | -0.8357 | 1.72 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
Beam Therapeutics Inc | 360.91m | -134.74m | 2.73bn | 436.00 | -- | 2.99 | -- | 7.56 | -1.74 | -1.74 | 4.54 | 11.10 | 0.2681 | -- | -- | 827,777.50 | -10.01 | -24.54 | -11.79 | -29.26 | -- | -- | -37.33 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
Agios Pharmaceuticals Inc | 29.40m | -352.62m | 2.73bn | 383.00 | -- | 3.67 | -- | 92.78 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
Kymera Therapeutics Inc | 79.41m | -154.59m | 2.73bn | 186.00 | -- | 3.84 | -- | 34.41 | -2.50 | -2.50 | 1.29 | 11.59 | 0.1072 | -- | 29.69 | 424,668.40 | -20.86 | -23.03 | -22.67 | -27.64 | -- | -- | -194.67 | -207.82 | -- | -- | 0.0032 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 13.21m | 9.41% |
Shah Capital Management, Inc.as of 20 May 2024 | 10.97m | 7.81% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 8.41m | 5.99% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 6.07m | 4.32% |
Geode Capital Management LLCas of 31 Mar 2024 | 2.59m | 1.84% |
Rafferty Asset Management LLCas of 31 Mar 2024 | 1.68m | 1.20% |
Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 2024 | 1.67m | 1.19% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.67m | 1.19% |
Coatue Management LLCas of 31 Mar 2024 | 1.52m | 1.08% |
Pacific Investment Management Co. LLCas of 31 Mar 2024 | 1.47m | 1.05% |